Gilead­'s ex-in­vestor re­la­tions chief takes CFO job at Sang­amo; For­mer GE Health­care ex­ec takes the helm at Vec­tura Group

→ And so the ex­o­dus con­tin­ues. Sung Lee, who had been Gilead‘s head of in­vestor re­la­tions, was named CFO of Sang­amo Ther­a­peu­tics, a cell and gene ther­a­py com­pa­ny. Lee had al­so helmed Gilead’s fi­nan­cial plan­ning and analy­sis di­vi­sion. Lee is just the lat­est in a slew of ex­its that have fol­lowed John Mil­li­gan‘s sud­den res­ig­na­tion from the CEO role in Ju­ly 2018. He had worked there for 14 years.

→ UK-based res­pi­ra­to­ry drug de­vel­op­er Vec­tura Group has tapped for­mer GE Health­care ex­ec Will Down­ie as CEO. Down­ie will take over the reins from in­ter­im CEO Paul Fry — who took over the role in June at the de­par­ture of James Ward-Lil­ley. Fry will re­sume his du­ties as CFO. Pri­or to join­ing the com­pa­ny, Down­ie spent a decade as SVP at Catal­ent lead­ing the com­mer­cial ef­fort for glob­al sales and mar­ket­ing ac­tiv­i­ties. Be­fore that, he served as vice pres­i­dent and gen­er­al man­ag­er at GE Health­care and vice pres­i­dent of sales at Amer­sham Health.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER